PubRank

J E Garber

Author PubWeight™ 99.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996 7.09
2 Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999 5.09
3 Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997 3.84
4 An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1995 3.81
5 Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999 3.26
6 Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996 3.07
7 Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996 3.04
8 Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999 2.68
9 Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994 2.66
10 Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000 2.58
11 Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998 2.55
12 Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA 1993 2.51
13 Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995 2.50
14 Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 1998 2.33
15 Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999 2.14
16 Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999 2.14
17 Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998 2.13
18 Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000 2.05
19 Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001 1.95
20 Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001 1.81
21 Disclosure of familial genetic information: perceptions of the duty to inform. Am J Med 2000 1.77
22 Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 1998 1.67
23 Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001 1.51
24 The impact of the prospective payment system on the treatment of hip fractures in the elderly. Arch Intern Med 1989 1.48
25 Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995 1.46
26 Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992 1.43
27 Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000 1.41
28 Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007 1.28
29 Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 1996 1.24
30 An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 2000 1.21
31 Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000 1.19
32 Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. J Clin Oncol 2000 1.17
33 Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998 1.10
34 Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995 1.08
35 Gene for familial breast and ovarian cancer. Lancet 1993 1.07
36 Unilateral spondylolysis and contralateral pedicle fracture. Spine (Phila Pa 1976) 1986 1.05
37 Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 2000 0.99
38 Genetic testing in young women with breast cancer: results from a Web-based survey. Ann Oncol 2009 0.99
39 Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes. J Med Genet 2004 0.97
40 Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet 2010 0.94
41 Testing for cancer genes: decisions, decisions. Nat Med 1995 0.93
42 Cancer surveillance is often inadequate in people at high risk for colorectal cancer. J Med Genet 2003 0.92
43 Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. JAMA 2000 0.88
44 Behavioral risk factors among women presenting for genetic testing. Cancer Epidemiol Biomarkers Prev 2000 0.87
45 Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab 1991 0.86
46 Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 2010 0.82
47 Waldenström's macroglobulinemia and autoimmune disease in a family. Ann Intern Med 1980 0.82
48 Adjuvant systemic therapy for patients with node-negative tumors. Cancer 1990 0.81
49 Genetic susceptibility for breast cancer--risk assessment and counseling. Semin Oncol 2001 0.80
50 Carcinoembryonic antigen in breast nipple aspirate fluid. Cancer Epidemiol Biomarkers Prev 1998 0.79
51 Comprehensive management of disseminated breast cancer. Cancer 1990 0.79
52 Ectopic bone formation in children and adolescents with head injuries: its management. J Pediatr Orthop 1987 0.79
53 Prostate-specific antigen in nipple aspirate. Lancet 1996 0.79
54 Testing and counseling adults for heritable cancer risk. J Natl Cancer Inst Monogr 1995 0.79
55 Defining etiologic heterogeneity in breast cancer using genetic biomarkers. Prog Clin Biol Res 1997 0.79
56 Family history and breast cancer. Probabilities and possibilities. JAMA 1993 0.78
57 Long-term outcomes of children exposed to antineoplastic agents in utero. Semin Oncol 2000 0.77
58 "First do no harm" also applies to cancer susceptibility testing. Cancer J Sci Am 2006 0.76
59 Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education. JAMA 1998 0.75
60 The value of studying cancer families. J Clin Oncol 1990 0.75
61 Testing for inherited cancer susceptibility. JAMA 1996 0.75
62 Follow-up of cancer family with in-vitro radioresistance. Lancet 1990 0.75
63 Carcinoma of the gall bladder in three members of a family. Cancer Genet Cytogenet 1989 0.75
64 Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review. Am J Clin Pathol 1988 0.75